Global demand for recombinant proteins has steadily accelerated for the last 20 years. These recombinant proteins have a wide range of important applications, including vaccines and therapeutics for human and animal health, industrial enzymes, new materials and components of novel nano-particles for various applications. The majority of recombinant proteins are produced by traditional biological “factories,” that is, predominantly mammalian and microbial cell cultures along with yeast and insect cells. However, these traditional technologies cannot satisfy the increasing market demand due to prohibitive capital investment requirements. During the last two decades, plants have been under intensive investigation to provide an alternative system for cost-effective, highly scalable, and safe production of recombinant proteins. Although the genetic engineering of plant viral vectors for heterologous gene expression can be dated back to the early 1980s, recent understanding of plant virology and technical progress in molecular biology have allowed for significant improvements and fine tuning of these vectors. These breakthroughs enable the flourishing of a variety of new viral-based expression systems and their wide application by academic and industry groups. In this review, we describe the principal plant viral-based production strategies and the latest plant viral expression systems, with a particular focus on the variety of proteins produced and their applications. We will summarize the recent progress in the downstream processing of plant materials for efficient extraction and purification of recombinant proteins.

Recombinant DNA technology was initially used to express proteins that were difficult to produce in their native organisms. Increasing efforts, however, have been focused on designing new molecules with more desirable characteristics and/or functionality. Pharmaceuticals and industrial enzymes were the first recombinant biotech products on the world market and biopharmaceuticals were the majority of commercialized recombinant proteins (Pavlou and Reichert, 2004). Many protein-based drugs, similar to traditional small molecule pharmaceuticals, function as antagonists by binding to and thereby inhibiting the activity of their target, such as an enzyme or a receptor. Classical protein antagonists include full monoclonal antibodies (mAbs), their single-chain derivatives (ScFv) and mAb-fusion proteins. Recent research programs have also focused on non-antibody antagonists that consist of a scaffold protein displaying the inserted affinity peptide (Walsh, 2006). Recombinant DNA technology also provided an excellent alternative for developing safer vaccines. Subunit vaccines are based on immunodominant protein components of a pathogen, but do not contain its genetic material. Consequently they cannot replicate, cause disease, or introduce pathogens into non-endemic regions. Viral coat proteins are exceptional subunit vaccine candidates and in some cases are able to form virus-like particles (VLPs) when expressed in heterologous systems. In fact, the only recombinant subunit vaccines presently available are based on VLPs. They are highly immunogenic and able to induce both humoral and cellular responses (Chackerian, 2007).

In addition to the pharmaceutical industry, many other fields are also relying intensely on recombinant proteins. Areas as diverse as agro-food technology, chemistry, detergent production, bioremediation, biosensoring, petroleum, and paper industries all receive significant contribution from applications of recombinant proteins. For example, increasing needs for a diversity of food processing enzymes, for example, amylase, lipase, xylanase, pullulanase and pectin modifying enzymes, demand a substantial involvement of recombinant protein technology (Olempska-Beer et al., 2006).

In the coming years, there will be a significant increase in demand for high quality recombinant proteins. In response, biological systems used for the production of proteins must be scalable, cost-effective, safe and flexible enough to meet market requirements. Current systems rely on “bio-factories,” that is, mammalian, insect, yeast, and microbial cell cultures. The majority of the recombinant proteins are currently produced in Escherichia coli or mammalian cells with a few exceptions of yeast or insect cells (Yin et al., 2007). All of these bio-factories are based on fermentation technology of suspension cells in bioreactors, which requires an enormous upfront capital investment and, thereby, severely constrains their scalability. The use of plants as production systems for recombinant proteins has been actively investigated over the last two decades. Plants are attractive as protein factories because they can produce large volumes of products efficiently and sustainably and, under certain conditions, can have significant advantages in decreasing manufacturing costs (Hood et al., 1999; Giddings, 2001). Plant systems are far less likely to harbor microbes pathogenic to humans than mammalian cells or whole transgenic animal systems. In addition, one of the major advantages of plants is that they possess an endomembrane system and secretory pathway that are similar to mammalian cells (Vitale and Pedrazzini, 2005). Thus, proteins are generally efficiently assembled with appropriate post-translational modifications. These cost, scale, and safety advantages make plant-made pharmaceuticals very promising for both commercial pharmaceutical production and for manufacturing products destined for the developing world.

Three approaches are commonly used to express heterologous proteins in plants: (1) stable transformation of the
nuclear genome, (2) stable transformation of the chloroplastic genome, and (3) viral transient transformation.

In stable transformation technology, an expression cassette harboring the exogenous gene of interest is integrated into the nuclear or plastid genome of plant cells, which results in the acquired character to be stably inherited over generations. These lines can be propagated vegetatively or by seed and thus, readily scaled up for protein production. Stable nuclear transformation is often achieved using Agrobacterium tumefaciens, which delivers fragments of DNA into the plant cell nucleus at random positions. Alternatively, the “biologic” method (microprojectile bombardment) can be used for plant hosts that are difficult to transform by Agrobacterium (Hansen and Wright, 1999).

Due to their double membrane structure, chloroplast transformation can be achieved only by bombardment with tungsten or gold particles coated with fragments of DNA. Stable transformation of the chloroplast offers several distinct advantages in areas of transgene targeting, product yield, and regulatory compliance. Since the chloroplast genome allows for homologous recombination, transgenes can be precisely targeted to a specific locus of the genome to avoiding positional effect or accidental gene knock-outs. Each plant cell has several chloroplasts and each of these contains many circular genomes. Therefore, the shear copy number of the transgene enables high-level expression of the target recombinant protein. Since the chloroplast is inherited maternally, this technology reduces the risk of potential transgene escape by pollen dissemination. Similar to bacterial cells, however, the chloroplast is unable to perform typical eukaryotic posttranslational modifications, such as glycosylation. As a result, this technology cannot be used to produce proteins when such modifications are essential for their function (Bock, 2007).

The third strategy relies on replicating plant viruses. These viruses are small, can be easily manipulated, and their infection process is relatively simple. The above features make viral vectors an attractive alternative to stable transgenic systems for the expression of foreign proteins in plants. In this strategy, the gene of interest is inserted among viral replicating elements, episomically amplified, and subsequently translated in the plant cell cytosol. Most of the transient expression systems are based on non-food, non-feed plants like tobacco, therefore, requiring further purification prior to application.

Production of recombinant proteins with stably or transiently transformed plants has been performed both in green-houses and in field. Neither practice requires large investments in hardware or culture media, thus making scale-up more economical than fermentation cultures. The possibility of producing recombinant protein agents on an agricultural scale by “molecular farming” is extremely attractive.

Although the use of plants as expression systems for recombinant proteins was first conceived for oral delivery of antigenic proteins (Walsmey and Arntzen, 2000), plant-made recombinant proteins have also been purified and used in many different applications. An enormous number of proteins different in size, structure, origin and biological function have been successfully expressed in stably transformed monocot and dicot plants such as maize (Chikwamba et al., 2003), rice (Nochi et al., 2007), wheat (Breteron et al., 2007), potato (Youm et al., 2007), tomato (Huang et al., 2005), tobacco (Watson et al., 2004), lettuce (Sun et al., 2006), alfalfa (Huang et al., 2006), lupin (Smart et al., 2003), carrots (Marquet-Bluin et al., 2003), barley (Joesu et al., 2006), soybean (Moravec et al., 2007), and thale cress (Carrillo et al., 1998).

Many antigenic monomeric proteins from viruses (Webster et al., 2006) and prokaryotes (Alvarez et al., 2006) have been produced and in a few cases, their immunogenic properties have been successfully evaluated in human volunteers during phase I clinical studies (Tacket et al., 1998, 2000; Thanavala et al., 2005).

Complex oligomeric mAbs were first expressed in stable transgenic plants by Hiatt et al. (1989). Since then, the number and type of plant-expressed antibodies, such as secretory antibodies, antibody fragments and, more recently, immune complexes, have increased steadily. Several commercial candidates of mAbs have been developed, with five mAbs under clinical evaluation, and two having reached Phase II clinical studies (Fischer et al., 2003).

In addition to pharmaceuticals, recombinant proteins for a variety of applications have also been expressed in transgenic plants. Examples include alpha-amylase enzyme (Pen et al., 1992), the protein brazzein for commercial sweeteners (Lamprhe et al., 2005), and the fungal enzyme manganese peroxidase (Clough et al., 2006). Moreover the chicken avidin diagnostic protein (Hood et al., 1999) and the bovine trypsin enzyme (Woodard et al., 2003) from transgenic maize, and the human anti-microbial proteins lysozyme (Huang et al., 2002) and lactoferrin (Humphrey et al., 2002) from transgenic rice have been commercially produced and are currently marketed by Sigma Chemical Company (St. Louis, MO).

The major challenges facing transgenic plant technology lie in increasing the quantity of protein, the optimization of expression systems, and improvement of downstream processing. In this review, we will focus on transient production strategies using plant viral expression systems, with a particular focus on the variety of proteins produced, and their applications. We will also discuss the latest developments in the downstream processing of plant materials for efficient extraction and purification of recombinant proteins.

Plant Viral Vectors

The history of genetic engineering and applied virology are intimately connected; the first recombinant molecule assembled was a chimeric SV40 containing genes from the bacteriophage λ (Jackson et al., 1972). The unique properties of viruses such as ease of manipulation, high level amplification, site specific recombination, strong infectivity, enhanced translation and compact and repetitive morphological structure have enabled their broad application, from basic research to product development, including the generation of robust expression systems. Viruses with a variety of host ranges such as bacteriophages, mammalian retroviruses, invertebrate infecting baculoviruses, and plant viruses have been genetically modified to express heterologous proteins.

From the discovery of viruses in 1898 (tobacco mosaic virus, TMV) (Bos, 1999), to the first demonstration of RNAs role in virus replication by turnip yellow mosaic virus (TYMV) (Matthews, 1989), to the very recent discovery of gene silencing and its implication in host response to infection, gene regulation and transgene expression (Baulcombe, 1999; Lu et al., 2003; Waterhouse and Helliwell, 2003), plant virology has played a crucial role in the understanding of the most fundamental concepts of modern biology. In addition, plant viral elements such as promoters, terminators, translational enhancers and various cis-regulatory sequences have been extensively used in plant biotechnology.

Plant viruses have been used to introduce foreign genes in plants since the early 1980s and technical advances in molecular biology and plant virology have allowed the generation of many improved expression systems. These recent systems provide many advantages including rapid, high-level transgene expression, and, in the case of movement defective systems, better transgene containment due to the lack of vertical and horizontal gene transfer.

The earlier plant virus expression systems were based on the cauliflower mosaic virus (CaMV) of the Caulimoviridae family,
the only plant viruses with a double stranded DNA genome. However, limited packaging capacity and the restricted amount of viral DNA that can be removed without affecting essential functions hindered the application of these initial expression systems. Fortunately, technical advances in molecular biology such as generating cDNA from an RNA template have enabled us to expand our search for expression systems into single stranded RNA viruses, the most represented types of plant viruses in nature. Another technical breakthrough was the use of Agrobacterium tumefaciens to promote viral infection (Grimsley et al., 1986; Turpen et al., 1993). Generally, viral infection can be initiated by mechanical inoculation of infectious viral particles on leaves or alternatively by transfection of nucleic acids. The use of Agrobacterium tumefaciens, known as “agroinfection,” allows the direct and efficient targeting of cDNA to the plant cell nucleus (Fig. 1). The cDNA constructs in the plant expression cassette would result in an infectious, autonomously replicating nucleic acid after host cell nuclear transcription and processing. Moreover agroinfection allowed the use of viruses that in nature are not mechanically transmissible, but instead need a special insect vector to initiate the infection process. These viral vectors are commonly divided into gene substitution vectors, gene insertion vectors, modular or deconstructed vector systems and peptide display vectors.

Gene substitution or replacement vectors are based on the exchange of an endogenous viral sequence with a heterologous gene of interest. The first successful expression of a foreign gene ever achieved in plants was obtained using a substitution vector based on the CaMV. Usually, the coat protein (CP) gene is the viral coding sequence of choice to be replaced. However, with a few exceptions, the CP is essential for cell to cell and/or systemic movement and infection. However, caution has to be taken if leaves of the whole plants are intended to be infected. For example, a CP replacement vector was developed using the tomato bushy stunt virus (TBSV). In this case the CP is not essential for systemic movement of the virus in certain species of Nicotiana (Scholthof et al., 1993) and it was indeed demonstrated that the insertion of a heterologous gene supports a systemic infection (Scholthof et al., 1993). In TMV-based substitution vectors, where the CP is necessary for systemic infection, a chloramphenicol acetyl transferase (CAT)–CP gene replacement vector generated only local lesions and CAT activity was confined on the inoculated leaf (Takamatsu et al., 1987). In another recently developed TMV-based gene substitution vector (Musyachuk et al., 2007) the CP gene was exchanged with the gene of interest fused to a thermostable carrier molecule, the beta-1,3–1,4-glucanase enzyme (lichenase) of Clostridium thermocellum, to facilitate target expression, stability and purification. The heat tolerant property of the lichenase (65°C) allows easy target proteins purification by heat treatment which precipitates up to 50% of contaminating plant proteins. The protein of interest, fused at the N- or C-terminus of lichenase, or inserted in the central loop of an engineered version of the enzyme, is protected from the degradation and thus purified.

Gene insertion vectors consist of complete functional viruses with the addition of an extra open reading frame (ORF) for the target protein. They are capable of cell to cell and systemic movement and infection. Viruses with both spherical and rod shaped virions have been investigated. Viruses with rod-shaped particles have a better potential due to fewer constraints on the amount of nucleic acid inserted. However, there is still a limit on the genome size of the chimeric rod-shaped virion based vectors. It has been proven that chimeric vectors with genome size beyond certain limits resulted in unsustained virion assembly. Two of the most famous gene insertion vectors have been derived from TMV and potato virus X (PVX). Both viruses have a single stranded positive RNA genome. They use subgenomic promoters and consequently subgenomic RNAs to express some of their ORFs and have a helical virion symmetry which results in rod-shaped particles. A chimeric TMV was constructed with the CAT gene.

---

Fig. 1. Agroinfection method. Nicotiana benthamiana plant (A,B), leaves adaxial side (C) and abaxial side (D), Agrobacterium tumefaciens liquid culture (E), small scale infiltration procedure (F), GFP expression under U.V. light (G). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
inserted between the movement protein (MP) gene and the CP gene; the expression was regulated by an additional copy of the subgenomic promoter of the CP gene that, as a result, was duplicated in the hybrid vector. The vector was able to replicate, to form subgenomic RNAs, to assemble correctly, and to produce reporter gene activity. Nevertheless the duplication of the subgenomic promoter sustained homologous recombination causing instability and the consequent loss of the exogenous gene (Dawson et al., 1989). This problem was solved by using a subgenomic CP promoter derived from a different virus belonging to the Tobamovirus genus to prevent homologous recombination. Similar problems and solutions of recombination between duplicated subgenomic promoters were reported in a recent insertion vector system based on the grapevine virus A (GVA) for N. benthamiana (Havi et al., 2006).

Analogous to TMV, a PVX-based vector was generated using the duplicated promoter of the CP gene. However in this case the vector was stable and able to retain the additional coding sequence (Chapman et al., 1992). Nevertheless, recently it has been demonstrated that the size of the inserted gene of interest can play a crucial role in the stability of the modified PVX expression vector, with a positive correlation between the elimination rate of the gene of interest and its length (Avessani et al., 2007). Recombination can involve homologous CP promoter sequences but also other mechanisms mediated by both the host plant and the virus (Avessani et al., 2007).

Another well established system is based on Cowpea Mosaic Virus (CPMV) the type member of Comoviridae whose bipartite genome is constituted by single stranded positive RNA molecules. RNA-1 encodes for proteins involved in replication while RNA-2 carries the genetic information for the movement and structural proteins. The system is very versatile; it can be utilized in a totally transient fashion, co-infiltrating wild-type plants with two separate cDNA constructs representing RNA-1 to sustain amplification and RNA-2 harboring the gene of interest, or it can be utilized combining transgenic plants with virus-mediated transient expression. In this case the RNA-2 is used for stable transformation and the RNA-1, necessary to prime the active replication of RNA-2 and of the heterologous gene, is supplemented by agro-infiltration. It is worth noticing that a deleted version of RNA-2, unable to produce infectious clones, has also been utilized to prevent possible environmental containment concerns (Liu et al., 2005; Sainsbury et al., 2008).

In conclusion it is possible to obtain an inducible expression system if RNA-1 is supplemented by agroinfiltration and a constitutive stable expression system if it is supplemented by crossing with an RNA-1 stable transgenic line (Canizares et al., 2006).

Modular or deconstructed vectors are a new generation of viral expression systems. Their development was driven by the understanding that: (1) not all viral components are essential or beneficial for an expression vector and (2) viruses can be broken down into different genomic elements that would still operate together in the infection process as wild-type multipartite genome viruses. Moreover, agroinfection provided the technical possibility to co-deliver multiple different components. Hence in modular systems, viral components are separated into distinct portions and inserted into binary vectors contained in an Agrobacterium strain. The strains are mixed together and co-infiltrated into plant leaves. This strategy allows the replicative portion, the so called replicon, to be reduced in size, down to minimal to accommodate the insertion of transgene, while other viral components necessary for the vector function can be provided in trans during the infection process. At present, one of the most famous and broadly used vector is the deconstructed system based on TMV and developed by Icon Genetics (Halle, Germany), recently acquired by Bayer Innovation GmbH. The vector has been engineered to divide the TMV genome into two major cDNA modules: a 5' module which contains the viral RNA dependent RNA polymerase and the MP, and a 3' module that carries the gene of interest and the 3' untranslated region (UTR) of the virus essential for the efficient replication and amplification of the vector. In this particular case, viral functions are not complemented in trans but the two modules actually assemble together in vivo by a site specific recombinase delivered by a third Agrobacterium cell line. Furthermore, different 5' modules carry different organelle targeting signals which, fused in frame with the gene of interest after recombination and nuclear processing, allow a single construct to be combined pair wise with various targeting elements in separate constructs. This feature greatly facilitates the experimental procedure to test optimal expression in terms of accumulation in different sub-cellular compartments. An additional attribute of the vector, that permitted a dramatic enhancement of expression levels, was the introduction of several introns in the coding sequences of the 5' module (Marillonnet et al., 2004, 2005). Levels of expression are impressive and can reach up to 5 mg of recombinant protein per gram of fresh weight (FW). The system was extensively tested with different genes, encoding for antibodies and antibody-derivatives, interferons, growth hormones, bacterial and viral antigens, adjuvants and enzymes (Gleba et al., 2005), confirming each time its versatility and robustness.

Another interesting modular system was developed using the bean yellow dwarf virus (BeYDV) of the Geminiviridae family. Geminivirus are single stranded circular DNA viruses known to replicate through the rolling circle process, promoting high level of genome amplification in the nucleus of the infected cell. The BeYDV based system is depleted of the MP and CP gene and consequently the expression of the protein of interest is confined to the inoculation area. The basic version involves two modules, one containing the gene of interest inserted between the BeYDV long and short intragenic regions, LIR and SIR respectively. Both intragenic regions are necessary to sustain rolling circle replication. The gene of interest is driven by a strong plant specific constitutive promoter. The second module is responsible for the expression of the Rep protein which catalyzes various aspects of the rolling circle replication. Initially, the system was used as an expression vector in tobacco plant cell culture (Mor et al., 2003) but its use has recently been extended to whole leaves with agroinfection. The modular nature of this system also permits the co-expression of a variety of sequences of different viral or non-viral origin that are beneficial for replicon amplification and transgene expression. For example, genes of post-transcriptional gene silencing (PTGS) inhibiting proteins can be co-expressed to prevent PTGS and hence enhance target protein accumulation.

Display viral vectors have been extensively used to provide a molecular scaffolding for different kinds of peptides to be fused with the viral CP and, therefore, to be exposed and displayed on the surface of chimeric virus particles (CVPs). Coat protein genes of several plant viruses were genetically modified to support fusions with coding sequences of heterologous peptides in specific regions known to be well exposed on the virion surface (Johnson et al., 1997; Porta and Lomonossoff, 1998). Therefore, the virus and the plant host would provide the expression system to produce large quantities of the chimeric fusion protein. Clearly this is only feasible for well characterized viruses in terms of assembly, movement strategies and structure. Fusions must be compatible with the normal assembly and viral fitness, and must avoid any possible steric hindrance or interference with virus movement. Defining peptide features for their correct display on CVP is of particular interest among studies in this area (Bendahmane et al., 1999; Porta et al., 2003; Lico et al., 2006). Two strategies have been developed to overcome assembly problems for long or difficult
peptides. One strategy is to modify the 3’ terminus of the CP gene so that the CP stop codon would function in a leaky fashion. This would cause most of the CP produced to be unfused, while a small portion would be fused to the peptide displayed on the surface (Hamamoto et al., 1993; Sugiyama et al., 1995; Borovsky et al., 2006). The other strategy employs the 2A peptide of the small foot and mouth disease virus (FMDV). This sequence, inserted between the epitope coding sequence and the 5’ terminus of the CP gene, produces a ribosomal skip during the translational procedure (Donnelly et al., 2001; de Felipe et al., 2003), with the result that only a small portion of the translational products will consist in a fusion between the heterologous sequence and the CP (Fig. 2). The use of these strategies, however, opens the question of the precise dose of the antigen in the vaccine formulation. Many plant viruses have been used to display different kinds of peptides. The most widely used viruses for this purpose are the CPMV, the TMV and the PVX. Extensive research regarding the symmetry, shape and structure at atomic level for these viruses have allowed the precise definition of specific sites for peptide insertion to ensure the successful display of fusion peptides (Klug and Caspar, 1960; Lomonossoff and Johnson, 1991; Baratova et al., 1992a,b; Johnson et al., 1997; Parker et al., 2002).

Major efforts are now directed to the development of new viral vector typologies in terms of both improvement of the expression strategies and virus choice. Host plants have also been extended to a wider variety of species including herbaceous plants and cucurbitaceous family. Besides the viruses mentioned above, other viruses have also been investigated as useful vectors, such as tomato mosaic virus (ToMV) (Dohi et al., 2006); maize streak virus (MSV) (Palmer and Rybicki, 2001); bean pod mottle virus (BPMV) (Zhang and Ghabrial, 2006); beet necrotic vein virus (BNYVV) (Schmidlin et al., 2005); tomato golden mosaic virus (TGMV) (Hayes et al., 1989); potato virus A (PVA) (Kelloniemi et al., 2006); zucchini yellow mosaic virus (ZYMV) (Hsu et al., 2004); cucumber mosaic virus (CMV) (Nuzzaci et al., 2007); and cucumber green mottle mosaic virus (CGMMV) (Ooi et al., 2006).

Monoclonal antibodies

Antibodies are key molecules of the vertebrates’ immune system. They are responsible for the recognition and binding of target antigens with high affinity and specificity. Monoclonal antibodies (mAbs) are used in a wide range of applications,

---

**Fig. 2.** Display strategies. Wild-type viral genome organization and encoded proteins (a), standard CP fusion strategy (b), Foot and Mouth Disease Virus 2A peptide CP fusion strategy (c), leaky stop codon CP fusion strategy (d). RdRp, RNA dependent RNA polymerase; MP, movement protein; CP, coat protein; 2A, Foot and Mouth Disease Virus 2A peptide; LSC, amber leaky stop codon. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
including diagnosis, prevention and treatment of many diseases. For example, they are being successfully utilized as “targeting vectors” to direct drugs, radioisotopes and other therapeutic molecules to their target cells or tissues, as immunomodulators in pathology-related functions, as well as diagnostic tools to identify and localize molecular alterations. In addition to their pharmaceutical applications, mAbs can also be used to modulate plant traits, generate disease or pest resistant crops (Tavladoraki et al., 1993; Nolke et al., 2004; Peschen et al., 2004; Villani et al., 2005), and to study plant metabolic pathways (Nolke et al., 2005). Antibodies are complex glycoproteins consisting of four polypeptides, linked by disulfide bridges and non-covalent bonds. Despite their complexity, mAbs and their derivatives can be easily expressed in heterologous systems including plants (Fischer et al., 2003). However, mAbs produced by heterologous systems may not share the precise structural and functional properties of the native molecules. For example, mAbs produced by a bacterial expression system will lack post-translational modifications including glycosylation. Non-mammalian eukaryotic expression systems could fail to use the appropriate glycans groups resulting in different glycosylation patterns. Yeasts, for example, tend to hyperglycosylate (Harashima, 1994; Malissard et al., 1996); while plants preferentially introduce xylose and fucose residues and fail to use galactose and sialic acid (Gomord and Faye, 2004). Although proper glycosylation is required for functions of many mAbs, it is to be noted that different glycosylation patterns do not always lead to loss of function in vitro or in vivo, or cause side-effects in humans (Chargeleugue et al., 2000). Different strategies have been adopted to circumvent these limitations such as targeting mAbs to the endoplasmic reticulum, or abolishing glycosylation sites by mutagenesis to avoid inappropriate glycosylated products. In fact, it has been reported that the absence of glycans in some cases did not interfere with correct assembly and activity (Rodriguez et al., 2005; Nuttall et al., 2005). In addition a fascinating approach that requires sophisticated genetic and metabolic engineering resides in the inactivation of endogenous glycosyltransferases and/or expression of heterologous mammalian specific enzymes in the host plant system (Saint-Jore-Dupas et al., 2007).

Complete antibodies and their derivatives have been produced with stable plant transformation technologies (Ma et al., 2005). Thanks to the recent improvements of viral-based vectors, mAbs have been produced with transient expression systems to quickly achieve much higher production levels along with other complex proteins. Single chain fragments, that preserve antigen-recognition elements of the full length immunoglobulin, are often more effective as drugs or diagnostic tools than mAbs due to their increased ability to penetrate target tissues, reduced immunogenicity, and more rapid clearance. A chimeric gene insertion TMV based vector was used for the expression of a human scFv for treatment of non-Hodgkin’s lymphoma (NHL) (McCormick et al., 1999, 2003). The plant-derived scFv generated an antibody response in vaccinated animals, and was an effective vaccine in a murine NHL tumor challenge model. The TMV strategy provides the speed and versatility required for the development of a patient specific treatment and this anti-idiotype vaccine is currently undergoing clinical trials for safety and immunogenicity evaluation in humans. Another example is a scFv derivative (small immune protein, SIP) to treat transmissible gastroenteritis virus (TGEV), a porcine coronavirus. The SIP was expressed by a PVX gene insertion vector and by a CPMV based display vector using the 2A expression strategy. The aim was to provide passive protection against enteric infections upon oral delivery in crude plant extracts (Monger et al., 2006). The SIP folded correctly and preserved the ability to bind and neutralize TGEV in tissue cultures. Moreover, it provided in vivo protection against challenge with TGEV in piglets vaccinated orally with crude extracts of scFv-expressing tobacco plants. The same researchers also expressed a full length TGEV-specific IgA by co-infected plants with two separate PVX insertion vectors for the light chain (LC) and the heavy chain (HC) respectively (Alamillo et al., 2006). The IgA was correctly assembled in plant tissue and provided in vivo protection against TGEV in piglets after oral administration. A previous work (Verch et al., 1998) also indicated the possibility to produce a full size mAb in plants through the co-infection of two modified TMV based viral vectors. These results clearly indicated the possibility to obtain functional mAbs through plant expression systems.

Nonetheless, expression of heterooligomeric proteins such as mAbs might be inefficient due to the co-delivery of viral vectors built on the same virus backbone. In fact, this feature may result in early segregation and subsequent preferential amplification of one of the vectors in one cell. This problem has been recently overcome by utilizing two sets of vectors derived from non-competing TMV and PVX to express the two different mAb chains (Gritich et al., 2006). TMV and PVX may interact with different host proteins to sustain their replication and movement without interfering with each other. As a result, neither of the two vectors gains a replicative advantage over the other, allowing efficient co-expression of HC and LC in the same cells. The level of expression by each vector is independent within the same cell and can reach up to 0.5 mg/g FW of full assembled mAb in few weeks. This strategy represents a useful platform for rapid large-scale manufacturing of mAbs and other hetero-oligomeric proteins especially in situations requiring rapid responses such as pandemic threats and bioterrorism events.

Antigens

A vaccine is an antigenic preparation used to establish immunity to a disease. Vaccination has been one of the greatest revolutions in medical science and has dramatically improved the quality and length of life expectancy. Although vaccines are the most cost effective form of disease protection in healthcare, their cost is still too excessive for many people in the world, especially in developing countries. Vaccines can be therapeutic, to overcome an infection already established, or prophylactic, to prevent a future infection. The aim of vaccination strategies is to obtain efficient and safe vaccine formulations to induce a long lasting immunity against various pathogens. To achieve this goal, the vaccine component should generate not only a neutralizing antibody response, a long-term memory B cells stimulation, but also a T cell mediated immunity to eliminate infected cells which represent the pathogen reservoirs. Recombinant subunit vaccines, based on a single protein (antigen) or a single peptide (epitope) derived from the pathogen, are particularly attractive strategies when compared to classic inactivated, attenuated or live recombinant vaccines. Recombinant subunit vaccines offer potentially equivalent efficacy but are much safer and in some cases easier to produce. Plants offer unique advantages for the production of subunit vaccines in terms of scale, speed, costs, yield, and safety. The first work that describes the expression of the hepatitis B surface antigen in stable transgenic tobacco in 1992 marked the beginning for developing low cost vaccine formulations in plants (Mason et al., 1992). Researchers focused on expressing their antigens in edible plant tissues as oral vaccines, opening a new prospect for vaccine delivery (Mor et al., 1998). Since then, many research groups have adopted this system and carried out studies in the areas of improving target protein expression levels, analyzing the administration route and schedule, choosing the appropriate animal models, and exploring the use of possible adjuvants.
The first report in this area described the expression of the FMDV structural protein VP1 with a TMV-based gene insertion vector (Wigdorovitz et al., 1999). A yield of approximately 0.15 mg/g FW was achieved and subsequently the antigen was administered to mice without further purification. All mice immunized intraperitoneally developed a protective immune response against experimental challenge with virulent FMDV. A great number of antigens have been produced in plants with different immunologic results (Streatfield and Howard, 2003).

Altogether, these works demonstrated that plant-derived antigens retained their antigenicity and were able to induce active protective humoral and cell-mediated immune responses. The development of plant derived vaccines for human and veterinary uses against viral pathologies, tumors, allergies, bacterial infections, and diabetes-associated autoantigens has been extensively investigated (Table 1).

Yusibov et al., expressed the E7 oncoprotein from human papilloma virus (HPV) in N. benthamiana plants with a gene replacement vector. The antigen was subsequently purified from infected leaves using the thermotolerance properties of lichenase (Massa et al., 2007). Mice, immunized subcutaneously with the plant-produced E7, showed a specific antibody and cytotoxic T-cell response. The dose also protected the animals against challenge with E7 tumor cells. Moreover, the recombinant antigen was able to prevent tumor development when administered after virus challenge, supporting the ultimate goal to produce an anti-tumor vaccine with both therapeutic and prophylactic uses.

A fundamental revolution within the last few years came from the use of modular deconstructed systems. A recent work using the magnICON TMV based system is worth noting. Santi et al. (2006) focused on the production of antigens for agents of biological warfare, for example, the Yersinia pestis bacterium, the causative agent of plague. In this work the protective efficacy of the fraction 1 capsular antigen (F1) and the low calcium response virulent antigen (V) expressed at levels up to 2 mg/g FW in N. benthamiana leaves was evaluated. Guinea pigs, immunized with purified antigens, showed antigen-specific serum IgG titers and, more importantly, 75% of animals were protected from an aerosolized challenge of virulent Y. pestis. In a subsequent work Mett et al. (2007) expressed the same Y. pestis F1 and V antigens in N. benthamiana plants with an average yield of 0.38 mg/g FW with their lichenase optimized vector. The purified proteins were administered subcutaneously to non-human primates. Cynomolus Macaques, producing antigen specific IgG and IgA responses which resulted in complete protection against lethal challenge with Y. pestis.

Recent work show a particular interest on emerging and re-emerging diseases, as well as agents of biological warfare, and have extended plant-derived vaccine development to smallpox (Golovkin et al., 2007), anthrax (Chichester et al., 2007), dengue virus (Saejung et al., 2007), and avian influenza A virus (Nemchinov and Natilla, 2007). Altogether, these data collectively show the establishment of a portfolio of well characterized and novel, improved strategies for the expression of effective vaccines in plants.

**Viral display for vaccine formulations**

“Peptide” vaccines are a particular subclass of subunit vaccines based on the ability of immunodominant epitopes to induce specific immune responses. Epitopes are the most important regions of an antigen. They interact directly with surface receptors on B and T cells and induce an immune response. A single protein can have several epitopes with different immunological features and structures. Epitopes can be linear, conformational, or both. Epitope specificity is determined by the interaction with receptor molecules on B and T cells.
**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**Nanotechnology applications**

Due to their simple macromolecular organization, assembly capabilities, structure stability, easy scalability and facile purification, plant viruses can offer a cheap source of biopolymers and nanoparticles. Well-characterized viruses with stable, highly ordered and repetitive structures, such as TMV and CPMV, are of particular interests. For example, CPMV, cowpea chlorotic mottle virus (CCMV) and other icosahedral viruses have been used as nucleation cages for the mineralization of materials (Douglas and Young, 1998).

Another promising application is in noninvasive in vivo vascular imaging techniques (Manchester and Singh, 2006). CPMV for example has been fluorescently labeled to visualize blood flow for periods of at least 72 h to identify vessels and to monitor tumor neovascularization (Lewis et al., 2006). Moreover, CPMV can be modified to generate new surface properties for developing novel biomaterials, electrochemical biosensors, or nano electronic devices (Wang et al., 2002; Chatterji et al., 2004; Steinmetz et al., 2006). Rod-shaped viruses, like TMV, have been extensively used in the synthesis of a variety of metals nanowires, magnetic materials and semiconductors. TMV can be used as organic templates for the controlled deposition of gold, silver and platinum to prepare 1-D arrays (Dujardin et al., 2003). Self-assembled, modified CP monomers of TMV were also employed for the construction of photovoltaic components in a novel light-harvesting system (Miller et al., 2007). CVPs can be also incorporated in liquid crystal systems or used to generate thin films and fibers (Flynn et al., 2003). These examples clearly demonstrate the broad application and emerging potential of plant viruses in nanotechnology fields.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.

**PLANT VIRAL VECTORS**

**Downstream Processing of Plant-Derived Pharmaceuticals**

Over the last decade, plant-based production of pharmaceuticals has made remarkable progress as the expression of a diverse set of proteins has been demonstrated, several proteins have moved into clinical testing, and a plant-derived veterinary vaccine has been approved. Recent developments in transient expression systems and production in a controlled greenhouse environment are directly addressing the issues of low expression levels and underdeveloped regulatory standards for plant-made pharmaceuticals (PMPs).

In spite of this progress, barriers remain that prevent the broad adoption of this technology platform. One of these is the lack of translational research to bridge the gap between bench discoveries and their corresponding clinical products. In fact, many product failures during development are ultimately caused by problems of transition from laboratory prototype to industrial product, as stated by the FDA Critical Path Report (http://www.fda.gov/oc/initiatives/criticalpath). Product industrialization programs are routinely delayed or derailed by inadequate efforts in downstream manufacturing, scale-up development, and quality control. Therefore, as tremendous progress has been realized in recombinant protein expression, research focus has gradually been shifted to improvements in downstream processes including extraction, purification and recovery of the final products. Downstream processing is fundamentally important to the commercial viability of the specific PMPs and the PMP technology in general. An optimized downstream process will not only provide the additional cost-saving measures for the overall product cost, it will also enable the large-scale production of the products to meet the market demands. In addition, downstream process development is an essential step in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations.
The general downstream processing steps for extraction and purification of pharmaceutical proteins are similar to those of other systems. These steps include harvest and fractionation of the tissue containing the targeted protein, extraction of target protein into designed buffer, clarification of cell debris and particles from the extract, purification of the target protein, and dialing of the purified products into the desired container in the desired formulation buffer. The unique structure and biochemistry of plant cells and tissues present different challenges and opportunities for each of the above processing steps. In addition, the choice of host plant species, tissue and subcellular organelle targeting of the product will have profound impact on the strategy and outcome of downstream processing efforts. Since this review concerns primarily viral vector based transient production of PMPs, our discussion will focus on the downstream bioprocessing of proteins targeted to the cytoplasm of leafy plants. PMP production with seeds has been extensively reviewed by others (Menkhaus et al., 2004; Nikolov and Woodard, 2004).

Biomaterial harvest and fractionation

The first step of biomaterial processing is extraction and purification from tissue with a high concentration of the target recombinant protein. The selective harvest of the target tissue will reduce the volume of initial biomaterial, and in turn, reduce the unnecessary need to eliminate the extra host proteins introduced by the inclusion of non-target tissue, and the total operational cost. The selectivity will also allow the avoidance of tissues which are hard to process, prime to introducing environmental contaminants (e.g., roots), or rich in other undesirable molecules such as proteases, alkaloids, and phenolics.

For transient expression with viral vectors, leaves are primarily the target tissue for protein accumulation. Currently most of the biomaterial production with these vectors is accomplished in greenhouses with a controlled environment. For example, 4–18 days after inoculation, N. benthamiana leaves will be selectively harvested away from roots and stems (Werner et al., 2006). For small scale preparation, some researchers perform further fractionation of leaves by manually separating the central vein from the rest of leaves. For large-scale production, this kind of operation becomes impractical and whole leaves are processed thoroughly in the next step. If the biomaterial is produced in open fields, extra steps have to be performed to remove the diverse array of environmental contaminants. Rinsing and light washing of plants, before harvesting the target tissue, is a common practice for this purpose. Regardless of where the biomaterial is generated, it is important to lower the bioburden and other contaminants as much as possible at this step. This measure will prevent microorganisms and other contaminants from entering purification feed streams and thus, greatly simplify the subsequent purification process and ensure the regulatory compliance of the final product.

One of critical factors in choosing plant expression platforms is the protein stability in the targeted tissue. With all the advantages of the viral based transient expression system, recombinant proteins generally do have less long-term stability in leaves due to higher water content in contrast to the seed-based stable transformed expression systems (Doran, 2006). However, some proteins did show relative long-term stability in leaves due to higher water content in contrast to the seed-based stable transformed expression systems (Doran, 2006). Depending on the nature of the target protein, some of them need to be further processed as fresh leaf tissue, while others can be stored up to months as frozen tissue without losing their recovery and/or biological activity (Chen, unpublished work). The possibility of storing tissue at a cold temperature for certain proteins offers and expands the flexibility of this production platform.

Protein extraction

The major goal of this processing step is to release the target protein into a liquid buffer solution from the plant tissue. To achieve this goal in a leaf-based transient expression system, leaf tissue is first ground in the presence of a desired extraction buffer to break the tissue and cells. The tissue homogenate will then be further pressed to release the protein into the aqueous buffer. The crude extract will be clarified to separate the protein-containing buffer from plant debris, insoluble proteins (see below) and other particulate matters. In comparison to other production hosts, plants produce more solid debris (up to 30% of totally weight of the biomaterial (Menkhaus et al., 2004)). The larger and denser solids make it impossible to achieve effective clarification by filtration methods. As a result, continuous centrifugation remains the most effective and scalable technique for plant extract clarification. It should be noted that it is possible to extract small recombinant proteins (<50 kDa) that are targeted through the endomembrane system to the apoplast without breaking the plant cells. For example, some of the smaller proteins can be released directly into the extraction buffer by simply rinsing the tissue or by a specialized centrifugation technique (Lohaus et al., 2001). The purification process for this class of proteins can be greatly simplified with the result of a reduction in host protein contaminants.

The choice of extraction buffer has to be carefully determined based on the properties (e.g., pl, size, hydrophobicity, and stability) of the target protein and the major contaminating host molecules. For example, the major contaminating protein in plant leaves is ribulose 1,5-bisphosphate carboxylase-oxygenase (RuBisCo). Correspondingly, the choice of low pH buffers (~pH 5.3) should be encouraged to keep RuBisCo insoluble and prevent it from being extracted into the aqueous phase. At laboratory bench scale, protease inhibitors and antioxidants are routinely added to the extraction buffer to counter the denaturation, degradation and structural modification by proteases and phenolic compounds. Due to regulatory restraints and low-cost requirement, these molecules should only be included when deemed absolutely necessary for large-scale production.

Purification

Both chromatographic and non-chromatographic methods have been employed to purify plant-derived pharmaceutical proteins. Like proteins from other production hosts, purification strategies are formulated for each individual protein based on its solubility, size, pl, charge, hydrophobicity, and affinity to specific ligands and the parallel characteristics of host proteins. For mAb-based PMPs, while protein A or G-based chromatography provides a superb and convenient steps (Langone, 1982), much effort is needed to eliminate plant host molecules which cause resin fouling or/and interfere with the binding of the target protein to protein A resin, and thus, reduce its capacity. Non-chromatographic scalable processes such as aqueous two-phase partitioning systems (ATPS) are being developed to address this key issue (Platis and Labrou, 2006).

For other non-mAb-based vaccines and therapeutics, a purification scheme has to be developed individually which is based on multiple steps of conventional chromatographic methods (Menkhaus et al., 2004). This time-consuming and challenging process calls for the need to develop more “universal” or versatile purification methods. The employment of affinity tags, particularly the tandem affinity tag purification (TAP) strategy, provides possibilities for such versatile solution
viruses and other infectious agents, it must be validated by standard pharmaceutical industry should be included to obtain a highly purified product. Otherwise, recovery will drop to an impractical level. Whenever possible, resins widely used in the overall scheme to ensure the safety of PMPs produced using the platform (Magalhaes et al., 2007).

Once optimized and implemented at a commercial scale, these expression systems should create a technology platform to meet market demands. Plant expression systems based on viral vectors have the greatest potential to provide such technology. Once optimized and implemented at a commercial scale, these expression systems should create a technology platform to produce recombinant proteins with scalability, speed, efficiency, cost-effectiveness and safety.

**Conclusion**

A significant increase in demand for high quality recombinant proteins is already on the horizon. New biological systems for the production of these proteins must be developed to meet market demands. Plant expression systems based on viral vectors have the greatest potential to provide such technology. Once optimized and implemented at a commercial scale, these expression systems should create a technology platform to produce recombinant proteins with scalability, speed, efficiency, cost-effectiveness and safety.

**Literature Cited**

Alamillo JM, Monger W, Sola I, Garcia B, Perrin Y, Bestagno M, Burrone OR, Sabella P, Plana-Castells J, et al., 1998. 2004. Use of virus vectors for the expression in plants of active full-length and single chain anti-cancerous antibodies. Biotechnol J 1:1103–1111.

Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, Mason HS, Cardineau GA. 2006. Plant-made subunit vaccine against pneumonic and bubonic plague is safe and immunogenic. J. Gen. Virol. 87:2463–2470.

Barańska A, Gidewsich-Nił, Shishkov AV, Kashirin IA, Radavsky JL, Jarvekulg L, Saarma M. 2002. The topology of the surface of potato virus X: Tritium plated and immunological analysis. J. Gen. Virol. 73:229–235.

Barańska A, Gidewsich-Nił, Shishkov AV, Kashirin IA, Radavsky JL, Jarvekulg L, Saarma M. 2002. The topology of the surface of potato virus X: Tritium plated and immunological analysis. J. Gen. Virol. 73:229–235.

Baulcombe DC. 1999. Fast forward genetics based on virus-induced gene silencing.Curr. Opin Plant Biol 2:1109–1113.

Bendahman M, Koo M, Karrer E, Beachy RN. 1999. Display of epitopes on the surface of tobacco mosaic virus: Impact of charge and isoelectric point of the epitope on virus-host interactions. J. Mol. Biol. 290:20–30.

Bock RM. 2007. Plant biotechnology. Prospects for herbicide and insect resistance. Molecular engineering and molecular farming. Curr Opin Biotechnol 18:100–106.

Borovský D, Radabandis S, Dawson WY, Powell CA, Sanzarova DA, Morris TW, Shabatakov J, Hurren A, Delbono H, Delauro P. 2006. Expression of Aedes tropion-modulating osteoclastic factor on the virion of TMV: A potential larvicide. Proc Nat Acad Sci USA 103:1863–1868.

Boo L. 1999. Beijerinck’s work on tobacco mosaic virus: Historical context and legacy. Philos Trans R Soc Lond B Biol Sci 354:675–685.

Bronte V, Baldy T, Hellwell SM, Jones TD, Kamstrup S, Dalgalarrondo S, Glick F, Hamilton JI, Dadmun MA. 2001. Single chain antibody fragments for ocular use produced at high levels in a commercial wheat variety. J. Biotechnol 129:539–546.

Caleo M, Liu L, Perrin Y, Tsakovski E, Lomonosoff GP. 2006. A bipartite system for the constitutive and inducible expression of high levels of foreign proteins in plants. Plant Biotechnol J 4:183–193.

Carrillo C, Wiegandt A, Lemos JC, Mantovani V. 1998. Protective immune response to foot-and-mouth disease virus with VPI expressed in transgenic plants. J. Virol. 72:1688–1690.

Chackerton B. 2007. Virus-like particles: Flexible platforms for vaccine development. Expert Rev Vaccines 6:381–390.

Chen S, Sasaki T, Baulcombe DC. 1992. Potato virus X as a vector for gene expression in plants. Plant J 2:549–557.

Chergulescu D, Vine ND, van Doelde WJ, Drake PM, Ma JK. 2000. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res 9:187–195.

Chatterji A, Ochoa WF, Pain M, Rana BR, Johnson JE, Lin T T. 2004. New addresses on an adrenergic virus nanoblock: uniquely reactive Lys sites on cowpea mosaic virus. Chem. Biol. 11:855–863.

Chichester JA, Muschkyck K, de la Rosa P, Horsey A, Stevenson N, Ugalvina N, Radabrandis S, Palmer GA, Mest T, Viscuso V. 2007. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 25:3111–3114.

Chikwamba RK, Scott MP, Meija LB, Mason HS, Wang K. 2003. Localization of a bacterial protein in starch granules of transgenic maize kernels. Proc Nat Acad Sci USA 100:11127–11132.

Clough RC, Pappu K, Thompson K, Beifuss K, Lane J, Delaney DE, Harley R, Drees C, Howard JA, Hood EE. 2006. Mangoan peroxidase from the white-rot fungus Phanerochaete chrysosporium is enzymatically active and accumulates to high levels in transgenic maize seed. Plant Biotechnol J 4:53–62.

Dalgalarrondo S, Kuntzelhnl A, Jones TD, Xu F, Meuwethe H, Hamilton WD, Langenfeld JP, Boshuizen RS, Kamstrup S, Lomonosoff GP, Porta C, Cala C, Cassil J, Meloen RH, Rodgers PL. 1997. Plant-derived vaccine protects target animals against a viral disease. Nat Biotechnol 15:248–252.

Dawson WO, Lewandowski DJ, Hill MF, Bubrick P, Raffo AJ, Shaw J, Grantham GL. 2001. Desmonds PR. 1989. A tobacco mosaic virus hybrid expresses and loses an added gene. Virology 157:285–292.

de Felipe P, Hughes LE, Ryan MD, Brown JD. 2003. Co-translational, intrasolubilisation of polypeptides by the foot-and-mouth disease virus 2A peptide. J. Biol. Chem. 278:14114–14120.

Dohi K, Nishikiori M, Tami A, Ishikawa M, Mesi T, Mori M. 2006. Inducible virus-mediated expression of a foreign protein in suspension-cultured plant cells. Arch Virol 151:1075–1084.

Donini M, Lico C, Bascheri S, Conti S, Magliani W, Polonelli L. Benvenuto E. 2005. Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl Environ Microbiol 71:6360–6367.

Downey ML, Luke G, Mehrora A, Liu X, Hughes LE, Gani D, Ryan MD. 2001. Analysis of the atherovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect. A potential ribosomal slip. J. Gen. Virol. 82:1012–1025.

Doran PM. 2006. Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol 24:436–432.

Dorklokhov YL, Shelevova AA, Frolova OY, Komarovs TV, Zvereva AS, Ivanov PA, Atabekov JJ. 2007. Superexpression of tuberculosis antigens in plant leaves. Tuberculosis (Edinb) 87:218–224.

Douglas T, Young M. 1998. Host-guest encapsulation of materials by assembled virus protein capsids. Nano Lett 3:413–417.

Escribano JM, Borca MV. 1998. Protective immune response to foot-and-mouth disease virus with VPI expressed in transgenic plants. J. Virol. 72:1688–1690.

Flynn CE, Lee S-W, Peelle BR, Belcher AM. 2003. Viruses as vehicles for growth, organization and assembly of materials. Acta Materialia 51:5880–5885.

Fujita T, Di Bonito P, Dibello F, Accardi L, Muller A, Civilli A, Simone P, Dorca M, Venuti G, Giorgi A. 2002. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res. 62:3654–3658.

Garcia JA, et al. 2003. Transgenic plants for protein production: A critical review. Curr. Opin Plant Biol 12:450–454.

Girlich A, Marroñer NL, Engler C, van Eidt G, Bottoner J, Klimsky V, Giebula Y. 2006. High yield expression of full-size IgG antibodies in plants infected with noncompeting viral vectors. Proc Nat Acad Sci USA 103:14701–14706.
Pavlou AK, Reichert JM. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Pen J, van Oeyen AJ, van den Elzen PJ, Rietveld K, Hoekema A. 1992. Direct screening for authentic antigenicity. Vaccine 21:4021–4029.

Perez de Mendoza DM, Zamarano PI, Dominguez MG, Taboga O, Del Medicina Jazic MP, Muntel P, Romero MA, Sarris MJ, Torra MV, Sadar AM. 2003. Bovine herpes virus 1 d protein produced in plants using a recombinant tobacco mosaic virus (TMV) vector possesses antigenic determinants. Vaccine 21:1133–1139.

Peschen D, Li HP, Fischer R, Kreuzaler F, Liao YC. 2004. Fusion proteins comprising a putative α-secretase antibody linked to antifungal peptides protect plants against a fungal pathogen. J Biol Chem 279:14163–14170.

Pfaff J, Dang N, Rasokhov L. 2007. Inactivation and purification of cowpea mosaic virus 3A peptides displaying antigen epitopes from Bacillus anthracis. J Viral Methods 146:1–153.

Platis D, Labrou NE. 2006. Development of an aequorin two-phase partitioning system for the fractionation of plant defense proteins from tobacco root exudates. J Chromatogr A 1117:121–124.

Porta C, Lomonossoff GP. 1998. Scope for using plant viruses to present epitopes from foreign antigens. Vaccine 16:1233–1234.

Porta C, Lomonossoff GP. 1998. Scope for using plant viruses to present epitopes from foreign antigens. Vaccine 16:1233–1234.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.

Porta C, Lomonossoff GP. 2004. Recombinant protein therapeutics—Success rates, market trends and values to 2010. 21:1513–1519.